© Copyright - Newspaper WordPress Theme by TagDiv
Clobetasol Propionate
Also known as / Synonyms: Clobetasol, Class 1 Superpotent Topical Steroid
Ultra-potent topical steroid used for up to 2 weeks to clear severe eczema, psoriasis, and resistant skin inflammation.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Short-term relief of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses.
- Severe chronic plaque psoriasis (excluding widespread plaque psoriasis).
- Recalcitrant severe eczema and atopic dermatitis unresponsive to lower potency topical steroids.
- Hypertrophic lichen planus, localized discoid lupus erythematosus, and granuloma annulare.
- Severe scalp psoriasis and alopecia areata (scalp lotion formulation).
Contraindications (Do Not Use If…)
- Rosacea, acne vulgaris, and perioral dermatitis.
- Primary cutaneous viral (herpes simplex, varicella), fungal (tinea, candidiasis), or bacterial skin infections.
- Perianal and genital pruritus.
- Use in children under 12 years of age.
- Use on the face, groin, axillae, or other intertriginous skin folds.
Important Clinical Precautions & Warnings
- Maximum 2-week treatment limit: do not use continuously for more than 2 consecutive weeks due to severe risk of hypothalamic-pituitary-adrenal (HPA) axis suppression and irreversible skin atrophy; limit weekly dose to 50 grams.
- Do not use with occlusive dressings: wrapping with plastic or airtight bandages dramatically increases systemic absorption and systemic toxicity.
- Irreversible cutaneous striae and atrophy: can cause skin thinning, permanent stretch marks (striae rubrae/distensae), telangiectasias, and purpura.
- Do not use on facial skin: triggers steroid-induced rosacea, severe perioral dermatitis, and skin thinning.
- Taper gradually or step-down: avoid abrupt cessation after prolonged use to prevent rapid rebound flares; step down to a medium-potency corticosteroid or topical calcineurin inhibitor.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Contraindicated in children under 12 years (children have higher skin surface area to body mass ratio, risking profound adrenal suppression). Geriatric: Elderly patients have fragile, thin skin; use with extreme caution to avoid severe bruising and tearing.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Localized burning, stinging, erythema, skin dryness, pruritus, and localized folliculitis.
Serious Side Effects — Seek Urgent Medical Care
Irreversible skin atrophy (thinning), permanent striae distensae (stretch marks), systemic HPA axis suppression (Cushingoid syndrome), secondary infections, glaucoma/cataracts (if used near eyes), and rebound psoriasis pustulosa.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Other systemic or topical corticosteroids: additive systemic glucocorticoid exposure and heightened risk of adrenal suppression.
- No significant pharmacokinetic CYP interactions when used in recommended topical quantities.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
Use with caution — see notesTopical corticosteroids are teratogenic in animals when absorbed systemically. High-potency steroids applied to large body surface areas during pregnancy carry increased risk of low birth weight. Use only if clearly needed on small areas for brief periods.
Lactation & Breastfeeding:
Use with caution — see notesIt is not known whether topical clobetasol achieves measurable breast milk concentrations. Avoid application to the breasts and nipples before nursing.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store below 25°C (77°F). Do not freeze. Keep tube tightly closed.
⏱️ Missed Dose Protocol:
Apply a thin layer as soon as remembered. If close to the next scheduled application, skip and resume regular routine. Never double apply.
Chronic overuse over large body surface areas leads to systemic hypercorticism: Cushing's syndrome (moon facies, central obesity), hyperglycemia, glycosuria, hypertension, and adrenal crisis upon cessation. Requires gradual tapering under endocrinological supervision.
Clinical Sources & Regulatory References
Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.
Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:
Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).
CDSCO Official Portal →U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.
Search FDA Labels on DailyMed →WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).
WHO Essential Medicines Registry →National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.
Query PubMed Studies for Clobetasol Propionate →
4mg Clinical Pharmacology Team. Clobetasol Propionate Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/clobetasol-propionate/
